ライフサイエンスコーパス: never smoker

1 a, and being an former smoker (compared to a never smoker).

2 ncluding 2433 current, 6518 former, and 6956 never smokers).

3 mer smoker or a current smoker compared to a never smoker.

4 1, 2.9) younger than 50 y when compared with never smokers.

5 -12 Mental Component Scale scores similar to never smokers.

6 e similar angina levels and mental health as never smokers.

7 No notable associations were observed among never smokers.

8 associated TF (MP-TF) activity compared with never smokers.

9 oncogenes among 89 lung adenocarcinomas from never smokers.

10 n 2010 revealing measurement bias in healthy never smokers.

11 ng greater opportunities for detection among never smokers.

12 atio, 1.21; 95% CI, 1.06-1.39) compared with never smokers.

13 ationship between ambient PM2.5 and LC among never smokers.

14 centrations compared with those of asthmatic never smokers.

15 posity at any age was 14% overall and 21% in never smokers.

16 rent smokers, whereas no cases were noted in never smokers.

17 nd depression scale scores than exsmokers or never smokers.

18 al cancer, kidney cancer, and lung cancer in never smokers.

19 se in CFTR function in smokers compared with never smokers.

20 never smoked and a reference group of twelve never smokers.

21 k among current cigarette smokers than among never smokers.

22 were identified; 340 patients were lifetime never smokers.

23 than current smokers, but greater risk than never smokers.

24 onfidence interval, 1.49-6.16) compared with never smokers.

25 uctions were observed among both current and never smokers.

26 smokers had similar risks for BCC and SCC as never smokers.

27 y (HR 1.38, 95% CI 1.04 to 1.83) compared to never smokers.

28 chocardiographic features when compared with never smokers.

29 s, respectively, and was observed even among never smokers.

30 s had a mean age of 61.5 years, and 47% were never smokers.

31 ore MT and poorer periodontal condition than never smokers.

32 were either attenuated or absent in past and never smokers.

33 take were present in both current/former and never smokers.

34 in tumors collected from current, past, and never smokers.

35 s. never smokers, and 39 genes in former vs. never smokers.

36 9; 95% CI: 0.94, 1.76; p-trend = 0.04) among never smokers.

37 among heavy smokers (mean 35 pack-years) and never smokers.

38 eatest among those younger than 70 years and never-smokers.

39 of former smokers becomes similar to that of never-smokers.

40 escribed as having stopped by choice) versus never-smokers.

41 st former smokers becomes similar to that of never-smokers.

42 a and IL-6 levels are higher in smokers than never-smokers.

43 methylation in smokers compared with that in never-smokers.

44 n both male and female smokers compared with never-smokers.

45 6 levels were comparable between smokers and never-smokers.

46 64.5% of patients were women, and 67.7% were never-smokers.

47 tal inflammation is worse among smokers than never-smokers.

48 ]) were significantly higher in smokers than never-smokers.

49 tion and in patients with COPD compared with never-smokers.

50 similar for FVC and persisted among lifetime never-smokers.

51 ified model (PLCOall2014) evaluated risks in never-smokers.

52 s a slight attenuation of the association in never-smokers.

53 actinomycetemcomitans, and T. forsythia than never-smokers.

54 r mutation profiles were similar to European never-smokers.

55 ressed in smokers without COPD compared with never-smokers.

56 comparing smokers with and without COPD, and never-smokers.

57 its ratio to forced vital capacity (FVC) in never-smokers.

58 smokers or ex-smokers with otherwise similar never-smokers.

59 r failure rates and bone loss in smokers and never-smokers.

60 417) were ex-smokers, and 52% (619,774) were never-smokers.

61 yed less bone loss than oxidized implants in never-smokers.

62 more than 10-fold higher in smokers than in never-smokers.

63 ts on P50 suppression than light smokers and never-smokers.

64 those with asthma (p=0.004) than in healthy never-smokers.

65 king cessation returned to levels seen among never-smokers.

66 n 14 mutations, 68% were women, and 36% were never-smokers.

67 fter 10-12 years the risk equates to that of never-smokers.

68 ation was 0.851 (95% CI = 0.840-0.862), with never smokers 0.806 (95% CI = 0.790-0.819), light smoker

69 for smokers [0.66 (95% CI: 0.43, 1.02)] and never smokers [0.65 (95% CI: 0.52, 0.81)].

70 oportion of sputum eosinophils compared with never smokers (1% and 4%, respectively) and lower fracti

71 s nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09-1.83).

72 iabetes in former smokers returns to that in never smokers 10 years after quitting, and even more qui

73 0 patients (screening cohort) encompassing 8 never-smokers, 10 smokers without airflow limitation, an

74 were 11 (95% confidence interval: 5.8-22) in never-smokers, 13 (6.2-29) in former smokers, and 18 (8.

75 ml; P = 0.002), which were not evident among never-smokers (-15.9 ml; P = 0.69 and -13.7 ml; P = 0.70

76 ividuals with a detailed smoking history (24 never-smokers, 16 smokers, and 8 ex-smokers).

77 ot significantly different between asthmatic never smokers (184 endotoxin units [EU]/mL; IQR, 91-310

78 Comparing former versus never smokers, 185 of the CpGs that differed between cur

79 ssion due to pneumonia were 1.9 (1.4-2.6) in never smokers, 2.8 (2.3-3.4) in former smokers, and 3.4

80 , 5,691 (6%) had self-reported asthma (2,304 never-smokers, 2,467 former smokers, and 920 current smo

81 CI, 1.12-2.30; P = .009); and for current vs never smokers: 2.00 (95% CI, 1.22-3.28; P = .006).

82 asured with a high-sensitivity assay in 3824 never smokers, 2341 former smokers, and 2550 current smo

83 Comparing current versus never smokers, 2623 cytosine-phosphate-guanine sites (Cp

84 Of these, 1476 (22%) were never smokers, 2696 (41%) former smokers, and 2451 (37%)

85 g/L; interquartile range, 2.0-4.1 ng/L) than never smokers (3.2 ng/L; interquartile range, 2.2-4.7 ng

86 smoking cessation and converged with that of never-smokers 30 years after smoking cessation.

87 sion due to COPD were 8.6 (95% CI 5.3-14) in never smokers, 30 (22-41) in former smokers, and 43 (32-

88 Patients were primarily men (90%), were never-smokers (51%), and had performed oral sex (97%), w

89 penhagen City Heart Study in our study: 2199 never-smokers, 5435 ever-smokers, 158 with asthma, 320 w

90 first full-term pregnancy <30y of age (79%), never-smokers (56%) with body mass indexes (BMIs) of <29

91 n the Cardiovascular Health Study, 2556 were never-smokers, 629 current smokers, and 1297 former smok

92 Among the 16 never-smokers, 69% had an EGFR mutation compared with 29

93 Among never smokers, a total vitamin D intake >/=400 IU/d was

94 Lung adenocarcinomas from never smokers account for approximately 15 to 20% of all

95 nflation levels were evaluated in 24 healthy never-smokers across three lung volumes (20%, 60%, and 1

96 ence of venous thromboembolism compared with never-smokers (adjusted relative risk 1.38, 95% confiden

97 Compared with never smokers, adjusted costs for the index hospitalizat

98 ter quitting and was equivalent to that of a never smoker after 20 years of cessation (P value for tr

99 atio, 1.42; 95% CI, 1.28-1.58) compared with never smokers after adjustment for age and other potenti

100 h the risk of tooth loss approaching that of never smokers after approximately 10 to 20 y of cessatio

101 lpha increased in smokers, CCL4 increased in never smokers and CCL5 and CXCL10 reduced in ex-smokers

102 ure and assessed associations separately for never smokers and ever smokers.

103 Never smokers and ex-smokers with MS had similar mortali

104 MS had similar mortality rates compared with never smokers and ex-smokers without MS in the male Brit

105 utations were detected in 40% (51 of 128) of never smokers and in 42% (15 of 36) of light former smok

106 rvival after PDAC compared to those who were never smokers and never drinkers.

107 The associations were stronger in never smokers and non-ICS users.

108 , and stronger associations were observed in never smokers and non-ICS users.

109 ers, and exsmokers) and 20 healthy subjects (never smokers and smokers) were recruited.

110 was more likely to be reported among female never smokers and those who had been exposed for >/=20 y

111 cer risk in any subgroup examined, including never smokers and women with body mass index (weight (kg

112 had worse HRQOL in all domains compared with never smokers and worse Short Form-12 Mental Component S

113 e overall implant survival rate was 96.9% in never-smokers and 89.6% in smokers.

114 This association remained significant in never-smokers and individuals without skin lesions, and

115 When the cohort was restricted to never-smokers and to former smokers who had quit at leas

116 ion of individuals have zero exposure (e.g., never smokers) and among those exposed the variable has

117 ifferentially expressed genes in current vs. never smokers, and 39 genes in former vs. never smokers.

118 ne (EGFR) mutations in adenocarcinomas among never smokers, and better prognosis.

119 form a sensitivity analysis in the subset of never-smokers, and these two probes are known to be stro

120 ls (50 patients with T2DM [25 smokers and 25 never-smokers] and 50 controls [25 smokers and 25 never-

121 ts examining all participants, ever smokers, never smokers, asthma-free participants, and more severe

122 In post hoc analyses among female never smokers, both PM2.5 (ORQ5 vs. Q1 = 1.79; 95% CI: 1

123 and lung cancer risk has been observed among never smokers but not among smokers.

124 s with mild-to-moderate asthma compared with never smokers, but little is known about the influence o

125 However, when restricting to never smokers compared with nondrinkers, the hazard rati

126 analyze changes to the LTA4H-PGP pathway in never smokers, control smokers, COPD smokers, and COPD f

127 Compared with never smokers, current smokers had greater left ventricu

128 Compared with never smokers, current smokers had significantly lower r

129 g smokers indicate 53% of smokers and 22% of never-smokers dying before age 80 years, and an 11-year

130 significantly younger and more likely to be never-smokers (each P < .001).

131 tio of 2.76 (95% CI 2.71-2.81) compared with never-smokers, even though 44% (37,240/85,256) of the ba

132 Compared with never-smokers, ever smokers experienced significantly sh

133 City Heart Study into six subgroups: healthy never-smokers, ever-smokers without asthma and COPD, tho

134 mpared between patient cohorts identified as never-smokers, ex-smokers, and current smokers.

135 Findings were similar among never smokers, except that differential %LAA in childhoo

136 5) were entered from an enriched population (never-smoker, female sex, nonsquamous histology, or Asia

137 quitting increased and was equal to that of never smokers following a cessation period of 10 years.

138 ger for other non-small cell lung cancer and never smokers for the "American/Western" pattern.

139 Compared with never-smokers, former smokers as a group had similar ris

140 ulted in 678 matched pairs in the current vs never smoker grouping and 945 pairs in the former vs nev

141 oker grouping and 945 pairs in the former vs never smoker grouping.

142 high FEV1 from each of the heavy smoker and never smoker groups.

143 Exsmokers compared with never smokers had an increased proportion of sputum neut

144 bservational analyses showed that current vs never smokers had lower risk of hay fever (odds ratio (O

145 The majority (98.6%) of never smokers had nondetectable cotinine.

146 Asian never-smokers had lung cancer signatures distinct from t

147 None of 65,711 PLCO never-smokers had PLCO(m2012) risk >/= 0.0151.

148 e hypothesis that, in individuals with COPD, never smokers have different characteristics and less se

149 Compared with never smokers, health care costs during the first year a

150 In never smokers, HIV was not associated with an increased

151 colectomy when comparing current smokers to never smokers (HR 0.98, 95% CI 0.67 to 1.44).

152 e need for surgery when comparing former and never smokers (HR 1.11, 95% CI 0.95 to 1.30).

153 sed risk of intestinal resection compared to never smokers (HR 1.27, 95% CI 1.08 to 1.49); however, t

154 found with respiratory mortality only among never smokers (HR = 1.27; 95% CI: 1.03, 1.56).

155 although the association was stronger among never-smokers (HR, 1.61; 95% CI, 1.01 to 2.57; P trend =

156 (95% CI: 0.94, 1.07) based on 2,215 cases in never smokers; HR=1.10 (95% CI: 1.01, 1.19) based on 1,0

157 7 was also associated with lung cancer among never smokers in the GENEVA dataset.

158 iated with lung cancer in uranium miners and never smokers in two external study populations.

159 on and comparing smokers, former smokers and never smokers in two Swedish cohorts, differing for know

160 ad worse periodontal status than smokers and never-smokers in the control group (P <0.05).

161 es and 215 female controls, 94% of whom were never-smokers, in the prospective Shanghai Women's Healt

162 is that the increase of lung cancer in Asian never-smokers is due to environmental factors such as se

163 n of the majority of these genes reverted to never-smoker levels following smoking cessation, althoug

164 xpiratory Flow, MMEF25-75%), AFP and CEA for never smokers, light and never smokers with cancer risks

165 e ex-smokers and smokers classified with the never-smoker-like cluster.

166 asing sputum endotoxin concentrations in the never smokers (linear regression alpha = .05, Spearman r

167 In never smokers, low 25(OH)D levels were associated with m

168 with advanced lung cancer who had clinical (never-smokers [<100 cigarettes per lifetime] or former l

169 ed in 3/89 tested tumors and 2/64 additional never smoker lung adenocarcinoma samples.

170 cavity cancer, we observed no association in never smokers (lung 0.99, 0.93-1.05; oral cavity 1.07, 0

171 Never-smoker males drinking </=1 glass/week had signific

172 Forty current smokers and 40 never-smokers, matched for age, sex, and mean PD of samp

173 ubjects (109 asthmatic patients, smokers and never smokers, mild, moderate, and severe; 53 patients w

174 oth urban and rural young men) had twice the never-smoker mortality rate (RR 1.98, 1.79-2.19, approac

175 th chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have

176 0.63; 95%CI = 0.41-0.97; P trend = 0.03) or never smokers (n = 308, HR = 0.58; 95%CI = 0.37-0.91; P

177 reased risk of ischemic events compared with never smokers (n = 4,135; hazard ratio [HR]: 1.24 [95% c

178 rs (n=69 [9%]), exsmokers (n=210 [28%]), and never smokers (n=461 [62%]) with severe asthma (n=760) r

179 men v 20 men; 69%), and a high proportion of never-smokers (n= 34; 52.3%).

180 ts were categorized as current, previous, or never smokers (NS) at listing for LT.

181 vaping electronic cigarettes (group 2), and never-smokers (NSs) (group 3).

182 e association studies were performed in 5070 never-smokers of the identification cohort LifeLines, an

183 eports do not provide separate estimates for never smokers or for blacks, who incongruously have lowe

184 tients into two categories of either all the never-smokers or all the smokers or ex-smokers.

185 rsely associated with overall lung cancer in never smokers (OR = 0.50; P = 0.02).

186 ociation of rs660895-(AG+GG) with PD seen in never smokers (OR = 0.64, p < 0.001) disappeared among e

187 /m (OR: 1.6, CI: 0.8-3.5), ever smokers with never smokers (OR: 1.4, 95% CI: 0.7-2.8), or total fundo

188 l [CI]: 1.3 to 2.4; P = 0.002) as well as in never-smokers (OR: 2.0, 95% CI: 1.2 to 3.5; P = 0.01).

189 re >50 y of age, were of normal weight, were never smokers, or had low prudent dietary pattern scores

190 1.11 to 1.69) comparing current smokers with never smokers ( P = .003).

191 5.3-10.0) years earlier, respectively, than never smokers (P < .001 for both).

192 43; 95% CI: 0.23, 0.84; P = 0.01) but not in never smokers (P = 0.8).

193 gnificantly lower in current smokers than in never smokers (P<0.001).

194 causes of low FEV1 between heavy smokers and never smokers (p=2.29 x 10(-16)) and between individuals

195 d IL-6 levels were higher among smokers than never-smokers (P <0.05).

196 LA and mortality tended to be stronger among never-smokers (P values for interaction 0.06 and 0.01, r

197 n COPD (p=0.003), and the decline in healthy never-smokers (p<0.0001).

198 decline of 20.9 mL (1.2) per year in healthy never-smokers (p=0.19).

199 was associated with lower CHD risk by 12% in never-smokers (P=1.3x10(-16)) in comparison with 5% in e

200 er-specific reference equations from healthy never smokers participating in 1991, 2002, and 2010 to d

201 Compared with never smokers, past smokers had a relative risk of incid

202 ation approaches for overall survival in 327 never smoker patients with NSCLC from The University of

203 is the most dominant type of lung cancer in never-smoker patients.

204 Among 3,757 never smokers, probable PTSD at baseline was associated

205 pausal breast cancer 0.89, 0.86-0.92) and in never-smokers (prostate 0.96, 0.93-0.99; premenopausal b

206 extraction did not decrease to the level of never smokers (rate ratio, 1.13; 95% CI, 1.04-1.24).

207 In never smokers, reductions in serum cotinine accounted fo

208 There were 313 (42.5%) never-smokers (reference group), 92 (12.5%) passive nons

209 among former smokers was similar to that for never smokers, regardless of time since quitting.

210 s were also more likely to have surgery than never-smokers (relative risk 1.12, 95% confidence interv

211 ks was significantly greater in current than never-smokers (relative risk 1.16, 95% confidence interv

212 (current smokers of >/=15 cigarettes/day vs. never smokers RR, 1.26; 95% CI, 1.23-1.30) and obesity (

213 , the high incidence of lung cancer in Asian never-smokers seems unlikely to be due to second-hand sm

214 ntifying screenees, and to determine whether never-smokers should be screened.

215 Currently, never-smokers should not be screened.

216 on of smoking and analyses carried out among never smokers showed similar results.

217 between lung adenocarcinomas of current and never-smokers showed modest differences, identifying onl

218 In never-smokers, significantly greater bone loss was found

219 s of air- or CS-exposed mice and in lungs of never smokers, smokers without airflow obstruction, and

220 Sixty-nine asthmatic patients (never smokers, smokers, and exsmokers) and 20 healthy su

221 and beta1 subunits was examined in lungs of never-smokers, smokers without airflow limitation, and p

222 ed and localized BAFF expression in lungs of never-smokers, smokers without COPD, and patients with C

223 alveolar epithelial type II (ATII) cells of never-smokers, smokers, patients with COPD, and two expe

224 The energy-LTL association was restricted to never smokers (standardized beta = -0.259, P = 0.0008; P

225 We enrolled 34 never-smoker subjects with nonsevere asthma.

226 fewer skin examinations and procedures than never smokers, suggesting greater opportunities for dete

227 l corticosteroids, particularly in asthmatic never smokers, suggests that airway endotoxin might cont

228 xpression confers stronger CHD protection in never-smokers than in ever-smokers.

229 the higher percentage of adenocarcinomas in never smokers, the greater prevalence of epidermal growt

230 Compared with never smokers, the multivariable hazard ratios in light

231 Compared with never smokers, the pooled RR from ten studies with 1 086

232 Compared with that for never smokers, the risk for diabetes was significantly e

233 ent smoking and diabetes risk: compared with never smokers, the RRs were 1.21 (1.10-1.33) for light s

234 Compared with never-smokers, the smokers' likelihood ratio for implant

235 Among never smokers there was also no evidence of an associati

236 life expectancy, respectively, compared with never smokers; those who quit smoking upon entering care

237 reast cancer diagnosis were more likely than never smokers to die of breast cancer (HR, 1.25; 95% CI,

238 smoke after diagnosis were more likely than never smokers to die of breast cancer (HR, 1.72; 95% CI,

239 In healthy never smokers, ultrasonic spirometers record lower lung

240 mance status (0-1 vs 2), and smoking status (never-smoker vs ever-smoker).

241 5 and PM10 may increase PD risk among female never smokers warrants further investigation.

242 2.8, and the ratio for former smokers versus never smokers was 1.0-1.8, depending on cessation age.

243 ity risk for current smokers versus that for never smokers was 2.8, and the ratio for former smokers

244 tones of 4 and 6 in ever-smokers compared to never-smokers was 1.34 (95% confidence interval: 1.12-1.

245 D in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smokers (95% confidence

246 status (current smokers, former smokers, and never smokers) was performed at Mayo Clinic in Rochester

247 mortality among smokers (in comparison with never-smokers) was mainly from diseases that, like lung

248 and 46 healthy control subjects, smokers and never smokers), we measured induced sputum MMP-12 concen

249 7 smokers with normal lung function, and 245 never-smokers, we measured a large number of clinical pa

250 asthma and 45 healthy controls [smokers and never smokers], we measured urinary tetranor prostagland

251 n current smokers and ex-smokers relative to never smokers were 2.70 (95% CI 1.59 to 4.58, p<0.001) a

252 f the CpGs that differed between current and never smokers were significant P<1x10(-7) (2623 CpGs at

253 -smokers] and 50 controls [25 smokers and 25 never-smokers]) were included.

254 ere inversely associated with lung cancer in never smokers, while age at first birth (for ages 21-25,

255 never smokers with no family history of PD, never smokers who did have a family history had an odds

256 c factors that influence overall survival in never smokers who have non-small cell lung carcinoma (NS

257 of COPD, with adjusted PRs ranging from 1.5 (never smoker with 1 to 5 teeth removed) to 6.5 (current

258 cipants), and 1.22 (1.10-1.35) for comparing never smokers with and without exposure to passive smoke

259 In 108 smokers and never smokers with asthma and 45 healthy controls [smoke

260 profiles are present in current smokers and never smokers with asthma and could provide an explanato

261 eased in smokers with asthma and differ from never smokers with asthma.

262 157) vs 192 (91, 301) pg/ml, P = 0.001 than never smokers with asthma.

263 ) -6, -7, and -12 concentrations compared to never smokers with asthma.

264 ere lower in smokers with asthma compared to never smokers with asthma.

265 %), AFP and CEA for never smokers, light and never smokers with cancer risks as high as those within

266 Compared with current and former smokers, never smokers with COPD had different characteristics an

267 Never smokers with COPD had different clinical character

268 sed in former and current smokers but not in never smokers with COPD.

269 al admissions was nonetheless substantial in never smokers with COPD.

270 Compared with never smokers with no family history of PD, never smoker

271 Compared with never smokers with no teeth removed, all combinations of

272 th care outcomes compared with exsmokers and never smokers with severe asthma.

273 Relative to a common reference group of never smokers with the lowest nitrate exposures, associa

274 y IL-1beta and IL-6 levels among smokers and never-smokers with and without prediabetes (controls).

275 al inflammatory conditions among smokers and never-smokers with and without T2DM.

276 ion levels were comparable among smokers and never-smokers with and without T2DM.

277 Never-smokers with asthma had an increased risk of asthm

278 the subgingival microbiota of smokers versus never-smokers with chronic periodontitis and matched pro

279 Forty smokers and 40 never-smokers with experience of advanced periodontal di

280 he serum and GCF MCP-1 levels of smokers and never-smokers with periodontitis and compare them with t

281 turned and oxidized implants in smokers and never-smokers with periodontitis.

282 terleukin (IL)-1beta and IL-6 in smokers and never-smokers with prediabetes remains uninvestigated.

283 L-6 levels were comparable among smokers and never-smokers with prediabetes.

284 Never-smokers with T2DM had worse periodontal status tha

285 parameters were comparable among smokers and never-smokers with T2DM.

286 conditions are comparable among smokers and never-smokers with T2DM.

287 l, candidate prognostic markers for NSCLC in never smokers, with eQTL analysis suggesting a potential

288 ose methylation reverts to levels typical of never smokers within decades after smoking cessation, an

289 Center workers in New York, including 6,133 never smokers without a previous diagnosis of asthma.

290 Of the 6,133 never smokers without asthma, 3,757 (61.3%) completed a

291 val = 1.19-1.72), with similar results among never smokers without asthma.

292 43 (32-59) in current smokers compared with never smokers without COPD.

293 For comparison we included 24,529 never smokers without COPD.

294 Compared with never-smokers without asthma, individuals with asthma ha

295 Among individuals with asthma compared with never-smokers without asthma, multivariable adjusted haz

296 sease III/IV) compared with both smokers and never-smokers without COPD.

297 14.74 (10.06-21.59) in asthma compared with never-smokers without lung disease (all p<0.0001).

298 cer, based on several observations: 1) among never smokers, women have higher lung cancer incidence r

299 Compared with parous never smokers, women who had smoked for more than 20 pac

300 Inverse associations were also seen in never-smokers, younger participants (<55 years), and tho